{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:12:21Z","timestamp":1791922341546,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Inc","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>A previous phase 2 study demonstrated the immunogenicity of a single dose of meningococcal A, C, W, Y-tetanus toxoid conjugate (MenACWY-TT) or polysaccharide (MenACWY-PS) vaccine for up to 5\u2009years in individuals aged 11\u201355\u2009years. This follow-up study evaluated long-term antibody persistence up to 10\u2009years and the immunogenicity and safety of a single MenACWY-TT booster dose given 10\u2009years after primary vaccination.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Blood draws were conducted annually in Years 7\u201310. At Year 10, all subjects received a MenACWY-TT booster dose. Blood was drawn at 1\u2009month and safety data were collected \u22646\u2009months postbooster. Study endpoints included immunogenicity during the persistence phase (primary), and immunogenicity and safety during the booster phase (secondary). Statistical analyses were descriptive.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 311 subjects were enrolled in the persistence phase (MenACWY-TT, 235; MenACWY-PS, 76); 220 were enrolled in the booster phase (MenACWY-TT, 164; MenACWY-PS, 56). Descriptive analyses indicated that at Years 7\u201310, the percentages of subjects achieving serum bactericidal antibody assay using baby rabbit complement (rSBA) titers \u22651:8 and \u22651:128 were higher for serogroups A, W, and Y in the MenACWY-TT versus MenACWY-PS group; percentages were similar across groups for serogroup C. rSBA geometric mean titers (GMTs) for serogroups A, W, and Y were higher in the MenACWY-TT group and slightly higher in the MenACWY-PS group for serogroup C. One month postbooster, all primary MenACWY-TT and \u226598.1% of primary MenACWY-PS recipients had rSBA titers \u22651:8. For all serogroups, rSBA GMTs postbooster were higher in the MenACWY-TT versus MenACWY-PS group. Most local and general reactogenicity events were similar between groups and mild to moderate in severity. Adverse events at 1\u2009month postbooster were 9.1% for the MenACWY-TT and 3.6% for the MenACWY-PS groups; all were nonserious.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Immune responses to a single MenACWY-TT primary dose administered at age 11\u201355\u2009years persisted in &gt;70% of individuals evaluated at Years 7\u201310. A MenACWY-TT booster dose administered at Year 10 was safe and immunogenic with no new safety signals observed. These results provide important insights regarding long-term protection from primary vaccination and the benefits of booster dosing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Clinicaltrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01934140\">NCT01934140<\/jats:ext-link>. Registered September 2013.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05104-5","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T10:04:12Z","timestamp":1592474652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55\u2009years"],"prefix":"10.1186","volume":"20","author":[{"given":"Charissa Fay Corazon","family":"Borja-Tabora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8958-1734","authenticated-orcid":false,"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Cheuvart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"De Schrevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"5104_CR1","doi-asserted-by":"publisher","unstructured":"McCarthy PC, Sharyan A, Sheikhi Moghaddam L. Meningococcal vaccines: current status and emerging strategies. Vaccines. 2018;6(1). https:\/\/doi.org\/10.3390\/vaccines6010012.","DOI":"10.3390\/vaccines6010012"},{"issue":"5","key":"5104_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/21645515.2018.1451287","volume":"14","author":"S Vuocolo","year":"2018","unstructured":"Vuocolo S, Balmer P, Gruber WC, Jansen KU, Anderson AS, Perez JL, York LJ. Vaccination strategies for the prevention of meningococcal disease. Hum Vaccin Immunother. 2018;14(5):1203\u201315.","journal-title":"Hum Vaccin Immunother"},{"key":"5104_CR3","unstructured":"Meningococcal meningitis. World Health Organization. 2018. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/meningococcal-meningitis. Accessed 22 May 2020."},{"key":"5104_CR4","doi-asserted-by":"publisher","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","volume":"134","author":"A Purmohamad","year":"2019","unstructured":"Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri MJ, Imani Fooladi AA. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.","journal-title":"Microb Pathog"},{"key":"5104_CR5","unstructured":"Meningococcal disease. In: Centers for disease control and prevention. epidemiology and prevention of vaccine-preventable diseases, 13th Edition. 2015. p 231\u2013245."},{"issue":"7","key":"5104_CR6","first-page":"1808","volume":"12","author":"M Broker","year":"2016","unstructured":"Broker M, Berti F, Costantino P. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum Vaccin Immunother. 2016;12(7):1808\u201324.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"5104_CR7","doi-asserted-by":"publisher","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","volume":"139","author":"AC Cohn","year":"2017","unstructured":"Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193.","journal-title":"Pediatrics"},{"key":"5104_CR8","unstructured":"Nimenrix\u00ae (meningococcal group A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics. Bruxelles: Pfizer Europe; 2017."},{"key":"5104_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12879-015-1138-y","volume":"15","author":"CF Borja-Tabora","year":"2015","unstructured":"Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial. BMC Infect Dis. 2015;15:409.","journal-title":"BMC Infect Dis"},{"key":"5104_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2334-13-116","volume":"13","author":"C Borja-Tabora","year":"2013","unstructured":"Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"5104_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1080\/21645515.2016.1248009","volume":"13","author":"BP Quiambao","year":"2017","unstructured":"Quiambao BP, Bavdekar A, Dubey AP, Jain H, Kolhe D, Bianco V, Miller JM, Van der Wielen M. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents. Hum Vaccin Immunother. 2017;13(3):636\u201344.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"5104_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","volume":"12","author":"R Baxter","year":"2016","unstructured":"Baxter R, Keshavan P, Welsch JA, Han L, Smolenov I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12(5):1300\u201310.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"5104_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","volume":"34","author":"R Baxter","year":"2015","unstructured":"Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J. 2015;34(11):1236\u201343.","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"5104_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","volume":"164","author":"R Baxter","year":"2014","unstructured":"Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164(6):1409\u20131415.e1404.","journal-title":"J Pediatr"},{"issue":"3","key":"5104_CR15","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","volume":"17","author":"L Ostergaard","year":"2013","unstructured":"Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2013;17(3):e173\u20136.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"5104_CR16","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","volume":"32","author":"RM Jacobson","year":"2013","unstructured":"Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013;32(4):e170\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"23","key":"5104_CR17","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.vaccine.2018.04.064","volume":"36","author":"M Knuf","year":"2018","unstructured":"Knuf M, Helm K, Kolhe D, Van Der Wielen M, Baine Y. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine. 2018;36(23):3286\u201395.","journal-title":"Vaccine"},{"issue":"36","key":"5104_CR18","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1016\/j.vaccine.2017.06.053","volume":"35","author":"MB van Ravenhorst","year":"2017","unstructured":"van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: a randomized controlled trial. Vaccine. 2017;35(36):4745\u201352.","journal-title":"Vaccine"},{"issue":"6","key":"5104_CR19","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/INF.0000000000001123","volume":"35","author":"NP Klein","year":"2016","unstructured":"Klein NP, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children. Pediatr Infect Dis J. 2016;35(6):662\u201372.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"5104_CR20","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"T Vesikari","year":"2015","unstructured":"Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34(12):e298\u2013307.","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"5104_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/INF.0000000000000750","volume":"34","author":"DA Ishola","year":"2015","unstructured":"Ishola DA, Andrews N, Waight P, Yung CF, Southern J, Bai X, Findlow H, Matheson M, England A, Hallis B, et al. Randomized trial to compare the immunogenicity and safety of a CRM or TT conjugated quadrivalent meningococcal vaccine in teenagers who received a CRM or TT conjugated serogroup C vaccine at preschool age. Pediatr Infect Dis J. 2015;34(8):865\u201374.","journal-title":"Pediatr Infect Dis J"},{"key":"5104_CR22","volume-title":"Enhanced Meningococcal Disease Surveillance Report, 2017 (CS283195)","author":"National Center for Immunization and Respiratory Diseases","year":"2017","unstructured":"National Center for Immunization and Respiratory Diseases. Enhanced Meningococcal Disease Surveillance Report, 2017 (CS283195). Atlanta: Centers for Disease Control and Prevention; 2017."},{"issue":"12","key":"5104_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05104-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05104-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:07:18Z","timestamp":1623971238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05104-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5104"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05104-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the International Council for Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. The study protocol and subsequent amendments were reviewed and approved by local institutional review boards\/independent ethics committees. All subjects or their parents or legal representatives provided written informed consent. For subjects aged <\u200918\u2009years, written informed consent was obtained from the subjects and their parents or legal guardians; subjects aged \u226518\u2009years or reaching 18\u2009years old after enrollment provided written informed consent directly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB-T\u2019s institution received grants from the GSK group of companies. PP, CW, MC, PL, and JP are employees of Pfizer. MVW, BC, NS, EA, and VB are employees of GlaxoSmithKline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"426"}}